TITLE:
The Use of Anti-Diabetic Drugs in Alzheimer’s Disease, New Therapeutic Options and Future Perspective
AUTHORS:
Osama H. Mohamed Ibrahim, Mariame A. Hassan
KEYWORDS:
Alzheimer’s Disease, Antidiabetic Medications, Beta Amyloid, Insulin Resistance, Cognitive Behavior, Metformin
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.9 No.6,
June
22,
2018
ABSTRACT: Alzheimer’s disease (AD) is a neurodegenerative disorder that is
characterized by progressive loss of memory, confusion, inability of speech and
decline in the cognitive behavior. It is considered one of the most common
forms of dementia. Clinical studies and preclinical data in the last decade
proved that AD and Diabetes mellitus share a pathophysiological pathway,
indicating that insulin resistance, oxidative stress and inflammatory response
would increase the risks of developing AD in diabetic patients. This review
presents briefly the etiology of AD and Diabetes, discusses the possible
theories about the interplaying risk factors and the mechanism of action of
anti-diabetic medications recommended for the treatment of AD. It is concluded
that antidiabetics have good potential to improve dementia, especially in
earlier AD stages. However, many of the underlying intricate molecular pathways
are still unclear and thus thorough future research is required.